Individualized treatment benefits advanced cancer patients

04/20/2009 | Forbes

An Arizona research team found molecular targets in 98% of 66 patients studied, and 18 people had longer progression-free survival times with targeted therapy compared to previous generalized therapies they had tried. A separate Italian study found genetic mutations in patients with advanced colorectal cancer that could indicate their tumors wouldn't respond to specific drugs.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN